Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials
ConclusionsOmalizumab seems to be the most effective therapy in InH-AAE. The continuous decrease of Fc εRI-receptor density on basophils under therapy with omalizumab along with clinical improvement observed in one patient, could serve as a new approach for further studies to evaluate FcεRI-receptor density as a surrogate marker for therapeutic efficacy and for dosing and determining injection inte rvals of omalizumab.Trial registration BASEC-Nr. Req-2016-00692. Retrospectively registered 24.11.2016.
Source: Clinical and Translational Allergy - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Clinical Trials | Databases & Libraries | Laboratory Medicine | Rare Diseases | Study | Xolair